U.S. Prescription Drugs Market Size Worth USD 67.51 Billion by 2034 | CAGR: 9.3%

The U.S. prescription drugs market size is expected to reach USD 67.51 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Prescription Drugs Market Share, Size, Trends, Industry Analysis Report: By Ailment (Alzheimer’s, Parkinson’s, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prescription drugs are described as physician-authorized medications formulated to treat specific health conditions with safety and efficacy standards, are evolving in response to dynamic industry trends. The growing use of personalized and precision medicine emphasizes the importance of tailoring treatments to individual genetic, biological, and lifestyle factors. This shift is encouraging greater demand for therapies that deliver targeted outcomes while reducing adverse effects, reshaping the way drugs are developed and prescribed. This trend is setting a new benchmark for treatment effectiveness and long-term healthcare value by aligning pharmaceutical innovation with patient-specific needs.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-prescription-drugs-market/request-for-sample

The increasing integration of digital health technologies into the development and delivery of prescription drugs further drives the market growth. Innovations such as digital therapeutics, AI-driven drug discovery, and connected health navigation platforms are transforming the design, testing, and monitoring of therapies in real-world use. These advancements accelerate the drug development lifecycle and also improve patient adherence and engagement, strengthening the overall impact of therapies. Together, these trends highlight the transformation of prescription drugs into a more technology-driven and patient-centric domain, positioning the market for sustained innovation and adaptability.

Top of FormU.S. Prescription Drugs Market Report Highlights

• In terms of ailment, the alzheimer's segment generated USD 2.31 billion in revenue in 2024, driven by growing rates of age-related cognitive decline and rising demand for long-term treatment solutions in the U.S.
• A few global key market players include AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb; Eli Lilly and Company; Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; Moderna, Inc.; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc.

Polaris Market Research has segmented the market report on the basis of ailment:

By Ailment Outlook (Revenue, USD Billion, 2020–2034)

• Alzheimer’s
• Parkinson’s
• Migraine
• Chronic pain
  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Post-Operative Pain
  • Fibromyalgia
  • Bone Fracture
  • Muscle Pain
  • Acute Appendicitis
• Sleep disorders
  • Insomnia
  • Hypersomnia
  • Sleep Apnea
  • Sleep Breathing Disorder
  • Circadian Rhythm Disorders
  • Parasomnia
  • Sleep Movement Disorders
• Major Depressive Disorder